Kamada misses Q4 estimates despite robust annual revenue growth
Kamada (NASDAQ:KMDA), a vertical integrated biopharmaceutical company specializing in plasma-derived therapeutics, reported fourth-quarter and full-year 2025 financial results on Wednesday.










